Establishment and application of path-based management mode of 5-HT3 receptor antagonists in chemotherapy patients / 中国药房
China Pharmacy
; (12): 493-496, 2023.
Article
in Zh
| WPRIM
| ID: wpr-962498
Responsible library:
WPRO
ABSTRACT
OBJECTIVE To establish the path-based management mode of 5-hydroxytryptamine-3 receptor antagonist (5- HT3RA) in chemotherapy patients, and to improve the rationality of medication in chemotherapy patients. METHODS 5-HT3RA standardized drug use control rules were formulated, with the help of medical intelligence and decision support (MINDS) system, path-based management was carried out for chemotherapy patients using 5-HT3RA in the form of whole-process information capture and prescription pre-review, and whole-process intervention was implemented on medication indications, usage and dosage, course of treatment, etc. The intervention effect was analyzed by comparing the changes in the use of 5-HT3RA without indication, unreasonable usage and dosage, repeated medication, unreasonable course of treatment, and per capita drug cost before and after the implementation of path-based management. RESULTS A total of 9 181 patients were included. After the implementation of path- based management, the proportion of unindicated drugs decreased by 0.48%, and the rate of unreasonable single dosage, unreasonable frequency, repeated medication, unreasonable treatment course (5-HT3RA still used 3 days after chemotherapy) decreased by 10.48%, 0.65%, 1.33% and 0.34%; per capita cost of 5-HT3RA decreased by 13.72 yuan; there were statistical significance (P<0.05). CONCLUSIONS 5-HT3RA path-based management mode effectively improves the rationality of medication and provides a new idea for rational clinical drug use.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
China Pharmacy
Year:
2023
Type:
Article